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ABSTRACT
Laboratory processing pathways have a significant impact on the overall
management of patients with sepsis. Retrieval and isolation of the suspected pathogen
from a patient blood culture specimen is required for a definitive diagnosis of bacterial
septicemia. Reference laboratories are high-volume facilities most often located some
distance away from the collecting facility. Given the lengthy work up already required
for blood culture pathogen analysis, reference laboratories must identify ways to
optimize every step of the blood culture pathway in the effort to decrease turnaround
time and mitigate lag time to final pathogen identification incurred by prolonged
collection-to-incubation times. Rapid molecular diagnostic methods independent of
culture results is an available potential solution. The focus of this paper is to consider
published literature on the evaluation of rapid blood culture testing to identify its
potential benefits and ultimately layout a properly developed implementation plan that
integrates the Verigene microarray-based rapid blood culture testing system
(Nanosphere, Northbrook, IL, USA) into the blood culture workflow at a high-volume
reference laboratory.
KEYWORDS: Blood cultures, gram-positive, sepsis, Verigene, workflow, process mapping,
reference laboratory, turn-around time
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Introduction: The need for rapid blood culture testing
Sepsis is defined as a life-threatening organ dysfunction caused by a
dysregulated host response to infection. This definition of sepsis was recently revised in
2015 to 1) reflect the overall understood syndromic pathobiology of the clinical
condition and 2) to differentiate its need for urgent recognition in comparison to other
types of infections (1). It is reported that approximately 582,000 episodes of septic
infections in North America are documented per year and at least 250,000 Americans
die from sepsis each year, making sepsis the leading cause of death by infection in the
United States (2,3).
An increase in mortality rate is directly related to delays in reportable results for
infections considered medical emergencies thus, in the case of sepsis, any delays prove
significant when appropriate therapy is dependent on pathogen identification and
susceptibility turnaround time (4,5). Retrieval and isolation of the suspected pathogen
from a patient blood culture specimen is required for a definitive diagnosis of bacterial
septicemia. This process can take between 1 and 3 days after a presumptive positive flag
has been identified (5).
Laboratory processing pathways have a significant impact on the overall
management of patients with sepsis and delays to appropriate patient care can be
observed anywhere from collection to reporting (8). Pre-analytical factors like whether a
blood culture is processed in the same facility where bedside collection took place or
processed at a core laboratory away from bedside collection location are important to
consider when the concern for turnaround time is as urgent as is with blood culture
testing. Core laboratories, also known as reference laboratories are high-volume
facilities that process anywhere between 100,000 specimens a year to over 1,000,000
specimens a year and are most often located some distance away from the collecting
facility (6). Given the lengthy work up already required for blood culture pathogen
analysis, reference laboratories must identify ways to optimize every step of the blood
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culture pathway in the effort to decrease turnaround time and mitigate delay time to
final pathogen identification incurred by prolonged collection-to-incubation times.
While the need for rapid microbiology results was discussed in literature dating
back to the 1980’s, rapid molecular testing platforms within microbiology laboratories
have only begun to be a norm during the last decade (8). Culture-based methods to
identify pathogens remain the gold standard and prove necessary as comprehensive
susceptibility information is required for appropriate therapy however, results obtained
from rapid molecular testing platforms, independent of culture, have recently been
acknowledged as necessary (9). The focus of this paper is to consider published
literature on the evaluation of rapid blood culture testing to identify its potential
benefits and ultimately layout a properly developed implementation plan that
integrates the Verigene microarray-based rapid blood culture testing system
(Nanosphere, Northbrook, IL, USA) into the blood culture workflow at a high-volume
reference laboratory. Due to unforeseen proprietary issues the high-volume reference
laboratory name and location will remain undisclosed.

Benefits to implementing rapid blood culture testing
Most documented benefits to adopting rapid blood culture testing are centered
around the clinical aspect of patient care. Separate studies performed by MacVane et
al., and Perez et al., demonstrate a significant impact to effective therapy selection as
well as a more rapid approach by providers to utilize narrow-spectrum antibiotics
(11,12). This prompt de-escalation of antimicrobial therapy is relevant not only to
hospitalized patient outcomes but also directly related to hospital costs. Documented
analysis of patient hospital length of stay and total hospital cost between two controlled
studies at one hospital, identified nearly $20,000 average reduction in cost when
comparing pre- and post-rapid pathogen identification platform integration (12). It is
important to note that the aforementioned studies demonstrate maximum benefits are
obtained when appropriate action is taken by antimicrobial stewardship programs in
place (11,12).
2

A more global benefit to implementing rapid blood culture testing is the
additional role that clinical microbiology laboratories can play on decreasing the
selective pressure for pathogen resistance. Rapid blood culture testing platforms
provide pathogen identification and information about clinically relevant resistance
markers with high accuracy when compared to conventional methods (10). Reducing
the time required for identification and susceptibility reporting from 48 – 72 h to less
than 24 h, after positive flag, may have a potential impact on lessening the spread of
multidrug resistant bacterial strains through the de-escalation of antimicrobial therapy.
The United States government, in line with Center for Disease Control guidelines,
identifies the need for the use of rapid and innovative diagnostic tests for the
identification and characterization of resistant bacteria (14). Delays associated with the
normal turnaround time of conventional microbiology methods leads to extended
periods of treatment with broad-spectrum empiric therapy and although considered the
appropriate choice for treating early stages of septicemia, can add to the selective
pressure for pathogen resistance (13). Sautter et al. looked at the role that Labs have
on lowering infection rates of multi-drug resistant infections and point out that
laboratory administrators should consider the value in information that laboratory
results provide on a larger scale when making decisions to support equipment that
provide rapid diagnostic results (13).
Time is of the essence when it comes to definitively diagnosing sepsis. Blood
culture bottles should be delivered to the processing laboratory soon after collection to
avoid instrument incubation loading delays and ultimately time to pathogen detection
delays (13). Pre-analytical delays incurred by processing blood cultures at a reference
laboratory may inadvertently pose a risk to patient treatment by prolonging the time to
detection of organisms. Although manufacturers specify collected blood culture bottles
may be held at 25°C for up to 24 h prior to loading into a continuous-monitoring blood
culture instrument without compromising results, a controlled study suggests
temperature and holding time before incubation can lead to an increase in time to
positive detection as well as a decrease in organism detection as a whole (13). Rapid
3

blood culture testing platforms offer clinically useful information on average 1.5-1.7
days sooner than the results obtained by conventional methods (11,15). If pre-analytical
factors like specimen transport cannot be modified then the opportunity for improving
turnaround times through testing platforms that provide rapid diagnostic results should
be strongly considered.
Comparable assays: Verigene vs FilmArray
The main focus of this paper is to develop an implementation plan to integrate
the Verigene assay into the positive blood culture workflow of a high-volume reference
laboratory. Although a number of nucleic acid diagnostic assays are available for rapid
pathogen detection directly from blood culture, the Verigene platform has been
previously chosen by administrators and validated for use by research and development
at the reference laboratory. Reasoning for choosing the Verigene platform over others
on the market was not disclosed. In an effort to make an informed conclusion about the
Verigene assay a brief comparison to FilmArray (BioFire Diagnostics, Salt Lake City, UT),
a similar rapid blood culture identification assay, will be made. Both Verigene and
FilmArray are qualitative multiplexed testing platforms that use slightly different nucleic
acid technologies to detect multiple pathogens and select genetic determinants directly
from positive blood culture bottles (16-18).
The Verigene molecular assay detects nucleic acid targets of the pathogens
listed in Table 1 via a microarray-based capture and mediator oligonucleotide system in
the self-contained single use blood culture gram-positive test cartridges (BC-GP) and the
single use blood culture gram-negative test cartridges (BC-GN). Verigene technology
(Processor SP and Verigene Reader) requires minimal hands on time for nucleic acid
extraction; after blood culture gram stain evaluation, 350uL and 700uL of well mixed
positive blood culture specimen is respectively added into the required BC-GP or BC-GN
test cartridge aliquot well and programed into the Processor SP (VPSP). In this closed
system, bacterial DNA is extracted, denatured, fragmented and allowed to hybridize
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with target specific oligonucleotides covalently bound to a glass microarray slide inside
the Verigene Test Cartridge (VTC).
TABLE 1 : IDENTIFICATION AND RESISTANCE TARGETS

Additional steps with mediator oligonucleotides, gold nanoparticle probes, and a silver
enhancement step is required to efficiently detect presence of bacterial targets (Fig. 1).
According to manufacturer specifications once hybridization is complete within the
VPSP, the VTC can be loaded into the Verigene Reader within 12 hours for accurate
detection. A 2- 2.5 h turnaround time from specimen loading to initial results is
documented. Technology specifics were obtained from Verigene BC-GP and BC-GN FDA
510(k) Summary submissions (17).

Figure 1. Basic illustration outlining the steps of Verigene technology. Capture and
mediated oligonucleotide assay utilizing gold-nanoparticle probe and silver
enhancement.

FIGURE 1 : BASIC ILLUSTRATION OF VERIGENE TECHNOLOGY

FilmArray Blood Culture Identification Panel (BCID) detects all of its bacterial
nucleic acid sequences (Table 1) simultaneously in one closed system known as the
Blood Culture Identification Panel (BCID), through two stages of PCR and an end analysis
5

of melt curves in replicate. The FilmArray platform has two main components 1) the
Loading Station and 2) the FilmArray Instrument (FilmArray Torch). Minimal hands on
time is also required to initiate nucleic acid extraction. After hydration fluid has been
injected to properly reconstitute the freeze-dried enclosed reagents, 200ul of positive
blood culture specimen mixed with sample buffer is added to the sample injection port
of the FilmArray Pouch. The FilmArray pouch is described as an enclosed circuit that
allows compartmentalized nucleic acid purification in which the first PCR reaction, the
second PCR reaction and the end melting temperature analysis takes place. The first PCR
reaction is a multiplexed PCR reaction performed to enrich the target nucleic acids in
the sample while the second PCR reaction is diluted and mixed with a double stranded
fluorescent binding dye to be performed in an array of individual wells, specifically for
each target in triplicate, for every diagnostic target. The presence or absence of
diagnostic targets are identified by DNA melt curve data collected and compared with
internal control data. Technology specifics were obtained from FilmArray (BCID) Panel
510(k) Decision Summary (18).
Pathogen identification differences between the two assays are present and
each platform has advantages over the other. The FilmArray BCID for example, detects
Haemophilus influenzae and Neisseria meningitidis both of which are not detected by
the Verigene BC-GN assay. Rapid diagnosis of both, H. influenzae and N. meningitidis, is
deemed clinically significant since in both cases patients may worsen rapidly. The
Verigene BC-GP panel identifies three Staphylococcus species to genus level:
Staphylococcus aureus, Staphylococcus epidermidis, and Staphylococcus lugdunensis
whereas the FilmArray assay only identifies Staphylococcus aureus to species level. In
2012, a review of sepsis incidence and sepsis pathogen recovery, implicated grampositive organisms as the most common organisms isolated from positive blood cultures
and accounting for 52% to 77% of bacterial sepsis (19). It is an advantage to rapidly
identify coagulase negative staphylococcus species (CNS) like S.epidermidis and
S.lugdunensis because of their more recently understood roles as pathogens (19,20).
Verigene BC-GP and BC-GN combined offer the ability to detect 9 of the most common
6

resistance markers including some of the most concerning carbapenamase resistance
genes (Table1). Since the first Enterobacteriaciae carbapenemase resistant organism
was identified in 1993 the concern to rapidly identify these multidrug resistant species
has grown (21). The FilmArray BCID assay does not offer detection for extended
spectrum beta-lacatam (ESBL) resistance genes, however, it does detect one other
gram-negative pathogen to species level that the Verigene BC-GN does not,
Acinetobacter baumanii. This Acinetobacter sp. is recognized as a major drug-resistant
organism implicated in nosocomial infections (16).
Assay limitations exist for both platforms and a number of them have been
compiled in Table 2. The following limitations described, although not all inclusive,
appear to show significant variability in performance and should be considered by
laboratory scientists upon final result review.
TABLE 2: ASSAY LIMITATIONS
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Both FilmArray and Verigene BC-GP/BC-GN demonstrate reduced sensitivity in
accurately detecting organisms directly from polymicrobial blood cultures (18,10).
When compared to other rapid identification platforms, literature documents that the
BC-GP assay more successfully identifies at least one organism from polymicrobial blood
cultures (21). Misidentification of organisms is shared between FilmArray BCID and
Verigene BC-GP/BC-GN; both platforms are unable to distinguish between Escherichiae
coli and Shigella sp., the BC-GP misidentifies Streptococcus mitis/oralis as Streptococcus
pneumoniae, BC-GN shows cross reactivity between Klebsiella oxytoca and Klebsiella
pneumoniae, BCID may not be able to detect all Streptococcus sp. and also shows
misidentification of Serratia marcesens as Pseudomonas aeuriginosa, Pseudomonas
putida or Pantoea sp. (10,18,21). Procedural limitations for FilmArray BCID include the
inability to use charcoal containing media for testing and the potential for pouch control
failures due to resin beads contained in blood culture media (18). The latter a source of
error requiring careful attention by the microbiologist upon initial set up. A gram-stain
is an essential part of positive blood culture work up procedures, nonetheless, it is
considered a procedural limitation of the BC-GP and BC-GN assays when compared to
FilmArray BCID. A correct gram stain interpretation is required in order to choose the
appropriate panel for identification on the Verigene platform (16,17).
Implementing molecular diagnostics in a clinical microbiology lab is largely
dictated by cost thus it is necessary to mention differences in cost between the two
platforms. A general list price inquiry comparison, reveals the unit price for Verigene to
be more affordable than the newest FilmArray platform (FilmArray Torch). CAP Today,
product comparison webpage, documents a list price of $40,000 for the Processor SP
and Verigene Reader required to run the Verigene BC-GP and BC-GN assays (22). It is
important to note that one Verigene Reader is adapted to connect up to 32 Processor SP
units; moreover, each Processor SP is capable of running one BC-GP or BC-GN at a time,
each of which cost $20,000 per unit (22). The list price for the newest FDA approved
(2016) FilmArray instrument, the FilmArray Torch, is $85,000 for the base model which
includes 2 modules and the system analyzer. Each module of the FilmArray Torch runs
8

one BCID pouch at a time and one analyzer can adapt up to 12 modules maximum.
Additional FilmArray Torch modules are $10,000/2modules (Alex Sterling, Biofire
Diagnostics, LLC, Sales Manager, personal communication). To further compare cost, it
is important to consider cost per test, however, a definitive value is dependent on a
number of variables that can differ among facilities. Blood culture positive volume at
the evaluated high-volume reference laboratory could not be disclosed thus cost
analysis was not included in this paper but the following values obtained from literature
review can be used to approximate a difference in cost per test between assays:
FilmArray BCID $129/per test, Verigene BC-GP/BC-GN $60-$99/per test (23-25). An
additional reference point for cost was obtained from a direct survey with a laboratory
manager at a 200-bed nonprofit community hospital whose microbiology department
uses the Verigene BC-GP and BC-GN for rapid blood culture detection. When asked if
BioFire FilmArray assay was considered upon integrating rapid blood culture testing, her
response was “BioFire is too costly and reimbursement may be a problem for their
panels. Verigene is a reasonable in price.” Although reimbursement for testing should
be considered, it may be more of an issue for a smaller hospital than it may be for a
high-volume reference laboratory.
Current blood culture positive workflow and suggested modifications
Besides minor changes like call notification documentation, the blood culture
workflow procedure at the evaluated high-volume reference laboratory has remained
the same for years. Moreover, new instrumentation with the potential to change
workflow processes has not been introduced in over 15 years. This section will aim to
delineate the current blood culture positive workflow steps from the pre-analytical to
the analytical as well as identify areas in need of improvement.
Before review of the current workflow was performed, a retrospective
evaluation of laboratory information system (LIS) documented turnaround time was
done for 108 nonduplicate specimens collected between December 2017 and February
2018. Average time from blood culture collection time to instrument load time, average
9

time to blood culture positive flag from documented load time, and the average time to
organism identification from blood culture positive flag time, can be seen in Table 3. All
blood cultures are collected in SA Standard Aerobic, SN Standard Anaerobic, PF
Pediatric FAN bottles and are incubated in the BacT/ALERT 3D (bioMérieux, Durham,
NC, USA) continuous monitoring instrument.
TABLE 3: AVERAGE TURN-AROUND TIME

Steps in the pre-analytical phase cannot be addressed within the scope of this
paper but it is important to acknowledge the average time of 8 hours that it takes for a
blood culture to be loaded onto the incubation instrument from time of collection (Fig.2).
The workup process for the current blood culture workflow follows the general principle
of subculture, gram stain review, and gram stain result notification to appropriate
provider. Emphasis is placed on prompt incubation of subculture media at optimal
conditions (37°C/CO2) to allow adequate bacterial growth for analysis early enough on
day two of blood culture positive workflow (Fig. 2).
The evaluated reference laboratory operates on a 24-hour 3 shift system with
groups of employees starting at various times: Shift 1 includes groups starting every
hour between 6 AM and 10 AM; groups in Shift 2 start every hour between 2 PM and 4
PM (including a limited number starting at 3:30PM); and all employees on Shift 3 start at
10 PM. Scheduling priority is given to the blood culture assignment to avoid gaps
between shifts that may potentially lead to unnecessary delays in processing blood
culture positives. Moreover, two skilled bacteriologists are scheduled per shift. All shift
10

members are to continuously perform tasks outlined in the analytical day 1 process (Fig.
2) up to 6 hours of their assigned shift allowing the last two hours for post analytical
documentation review of LIS documentation, slide archiving, and paper worksheet
completion. The post-analytical steps are not included in Figure 2 nor Figure 4 as they
do not affect the overall process of blood culture positive handling.

Figure 2. Current blood culture workflow. Swim lane process map depicting steps in the three phases of the
current blood culture workflow. Clock symbol indicates incubation time required. “Pulled” refers to positive blood
culture bottle removed from continuous monitoring incubation instrument.

FIGURE 2: CURRENT BLOOD CULTURE WORKFLOW

Although an advantage of using MALDI-TOF MS (Matrix assisted laser desorption
ionization-time of flight mass spectrometry) for pathogen identification on day 2 of
analysis exists, a review of the current blood culture workflow process highlights the
prolonged amount of time it still takes for organism identification information to reach
clinicians (Fig. 3). Summing the average amount of time it takes to update a report with
a pathogen ID obtained on MS, with the average time from collection to initial positive
blood culture flag, it is clear that efforts to decrease the time to identification still
requires improvement in order to prove beneficial to the patient treatment outcome
(Table 3).
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Figure 3. Timeline comparison, current workflow versus proposed workflow. Adjustment of therapy for
gram-positive pathogens can be achieved >24 hours sooner by integrating BC-GP assay.

FIGURE 3: TIMELINE COMPARISON

There are other areas, besides the need for rapid identification requiring
acknowledgment that time and resources may not be efficiently utilized within the
current workflow. For example, literature states the importance of gram stain result
notification, regarding it as a “critical value” carrying significant weight to correctly
direct appropriate patient care, however, the current pathway places gram stain review
second to subculture (26,27). A high-volume reference laboratory may have over six
incubation BacT/Alert 3D modules, each with 240 cells for monitoring, thus, the
expected throughput of positives per 8-hour shift can be quite high on any given shift.
Consideration to the amount of time it takes to organize, document, and subculture a
large number of positives before gram stain review should be acknowledged as time
directly affecting patient care. The logic behind inoculating solid agar media at the same
time as slide preparation is to allow for subculture to be performed as soon as possible
in order to maximize incubation time for better culture review on analytical day 2
(Figure 2). This however, is limited because review of blood cultures on analytical day 2
requires supplemental media (i.e. additional selective solid agar media, tube coagulase
to rule out Staphylococcus aureus, and disk diffusion screen plates) to be included.
Furthermore, this additional media to be added is dependent on gram stain
morphology. Since supplemental media cannot be added until gram stain review is
performed, incubation at the ideal 37°C/CO2 conditions is delayed. This process forces
12

the bacteriologist in and out of the biohood as follows: 1) To organize biohood with
necessary primary media (i.e. blood agar plates, chocolate agar plates, macconkey
plates) 2) To label and inoculate solid agar media and gram stain slide 3) To add
supplemental media to each respective blood culture and 4) To organize media for
incubation after gram stain notification; consequently, allowing room for a decrease in
overall work efficiency that may translate over to undesirable mistakes.
Standardization is an important step in optimizing any process and removing
variability can lead to better efficiency. The current workflow allows employees to
choose between two fixing methods before performing a gram stain: heat fix or
methanol fix (Fig. 2). Both fixing methods require blood samples inoculated on a glass
slide to air dry completely before fixing for optimal results and use of crystal violet,
iodine, decolorizer, and safranin immediately after fixing. A simple study done to
compare gram stain fixing methods, found methanol fixing to produce better looking
stains over those that were heat fixed such that, a higher number of organisms adhered
to slides and a decreased probability of gram-positives over-decolorizing were observed
with methanol fixation (28). The former posing great risk to patient care resulting in
missed organisms upon gram stain review and the latter commonly a source of error
with organisms like Bacillus sp. and Clostridium sp. even amongst experienced
bacteriologists (28). It appears counterintuitive to allow variability in a critical step of a
workflow process.
The last topic requiring discussion is that of inter-shift work endorsement. The
current process requires a last “pull” of positives 2 hours before end of shift to allow for
all work up and post-analytical review of LIS documentation to avoid carry over of
unfinished processes to the next shift. Flagged positive blood cultures during this last 2hours of this work up and documentation review time remain in the automated
incubator for the next shift to process. The attempt to minimize this “lag” time between
shifts is done by scheduling an overlap between the last person that leaves a shift and
the first person that arrives for a shift. Since scheduling problems may arise from time
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to time, it may be important to devise a set framework for continuous workflow to
avoid turn-around delays for clinically significant results.
Modified blood culture work-up method: Verigene implementation
The initiative to integrate rapid blood culture testing was seriously considered at
the evaluated high-volume reference laboratory back in 2015. For undisclosed reasons,
the implementation was never followed up. Per discussion with upper management
overseeing research and development at the reference lab, interest in introducing the
Verigene BC-GP assay into positive blood culture workflow processes exists and it is
apparent that it will be more seriously considered upon laboratory expansion later this
year. It is the goal of this section to introduce a modified blood culture workflow that
integrates rapid blood culture testing for gram positive organisms and considers
solutions to the aforementioned opportunities for improvement.
The modified workflow process, in contrast to the current method, puts
emphasis on gram stain review and call notification over subculture to address the
critical component of gram stain evaluation, as it relates to provider notification and
initiation of rapid identification assay (Fig. 4). Immediately after gram stain review, BCGP panels will be set up for all gram-positive cocci in cluster, gram-positive cocci in pairs
and/or chains, and any gram-positive rods isolated from aerobic blood culture bottles
not previously identified by rapid assay (Fig. 5). During the 2 h BC-GP assay turnaround
time, gram stain notification is performed per shift protocol, media is respectively
organized/labeled, subculture in biohood is performed, and subcultures are
appropriately incubated at optimal 37°C/CO2 conditions (Fig. 4). Since identification to
species level will be obtained for the most common gram-positive blood culture
pathogens (Table 1) on analytical day 1 (Fig. 4) the need for tube coagulase to rule out
Staphylococcus aureus and disk diffusion screen plates specific for gram-positive
pathogens is eliminated. Additionally, when the bacteriologist is ready to go into the
biohood for subculture, all necessary media will be labeled and ready for inoculation.

14

Figure 4. Proposed blood culture workflow. Swim lane process map depicting steps in the three phases of the proposed
blood culture workflow. Clock symbol indicates incubation time required. “Pulled” refers to positive blood culture bottle
removed from continuous monitoring incubation instrument. Diamond with encircled hexagon inside indicates decision
activity dependent on fulfilled situation. Dotted process flow line refers to alternate workflow pathway.

FIGURE 4: PROPOSED WORKFLOW

Upon incubation of first “pull” subcultures, the bacteriologist will ensure Blood
Culture Positive Worksheet is filled in (Appendix A) and necessary LIS documentation
has been verified before continuing on with the process. Moreover, before gram stain
reviews are performed on subsequent “pulls” or shortly thereafter, one of the two
scheduled bacteriologists should monitor the Verigene instrument (assigned as an
alternate workflow pathway and indicated as a dotted line on Figure 4) for pending BC-
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GP results and document any completed results in LIS per information outlined in Figure
6 and Table 4.
The proposed process map includes two additional steps in analytical day 1, not
present in the current process map, in an effort to address the need for continuous
workflow and promote a structured endorsement of work between shifts. Additionally,
changes to analytical day 2 were required to account for rapid identification performed.
At the beginning of a shift, the scheduled bacteriologists must acknowledge receipt of
any work from the previous shift and will assume responsibility to complete any
additional tasks required as outlined on “End of shift protocol” (Figure 4).
Conversely, one hour before end of shift all flagged blood culture positives must be
“pulled”, reviewed, documented on Inter-Shift Worksheet (Appendix B) and verified in
LIS. Both additional steps detailing inter-shift work endorsement are assigned as an
alternate workflow pathway and indicated as a dotted line on Figure 4. Rapid blood
culture testing performed on analytical day 1 has an impact on workflow for analytical
day 2. Figure 6 shows the decision algorithm required to evaluate BC-GP released
results. Any questionable results or non-phenotypic matches should be confirmed by
MALDI-TOF MS.

Figure 5. Decision flow chart for Verigene blood culture gram-positive assay (BC-GP) set up.

FIGURE 5: DECISION CHART FOR BC-GP SET UP
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TABLE 4: CALLS FOR VALID RESULTS

FIGURE 6: DECISION CHART FOR RELEASING RESULTS

Anticipated workflow benefits and challenges
Essentially, the BC-GP ID assay is not meant to take the place of any of the
current steps of the workflow process thus as expected, when comparing process maps
for the current and proposed method, the proposed method appears more
cumbersome. Benefits to workflow processes are not as obvious as one might presume
but they do exist.
17

Although it is clear that additional steps are required to set up a supplementary
method of identification on analytical day 1, hands on time for the Verigene BC-GP is
less than 5 minutes (16,17). Moreover, the proposed workflow, outlines rapid ID to be
limited to aerobic specimens without documented previous history hence anticipating a
minor interruption of overall workflow (Fig. 5). These additional steps required in the
analytical phase of day 1 will prove beneficial to the workflow in the analytical phase of
day 2 in that, isolates with rapid ID results should require minimal phenotypic
bacteriologist review before susceptibility workup can be initiated. A retrospective look
at organism identification, for 108 randomly selected non-duplicate positive blood
samples, demonstrated that over 80% of organisms identified by conventional method
could have benefited from rapid identification on analytical day 1 (Table5).
TABLE 5: MS ID FOR N=108
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When considering the total volume of blood culture positives that a high-volume
reference laboratory may incur, this percentage can directly translate over to
bacteriologist workup time which in turn translates over to laboratory cost.
In further analyzing the workflow processes of the proposed plan one can
identify other areas where bacteriologist time and efficiency can be improved. One area
worth mentioning is the twofold benefit of focusing on gram stain review immediately
after a blood culture positive is flagged; to the benefit of patient care, an immediate
gram stain review can lead to faster turn-around times of clinically significant
information reaching the clinician (Figure 3) and to the benefit of the bacteriologist,
blood culture gram stain information available at the time of initial subculture allows for
a streamlined process when gathering and organizing appropriate subculture media.
The task of including additional media based on gram stain review is made more
efficient in the proposed method by eliminating the need for tube coagulase inoculation
and plating of disk diffusion blood agar media. This media is added to help screen for
the most common gram-positive pathogens i.e. tube coagulase for Staphylococcus
aureus, Bacitricin (A disk) for Streptococcus pyogenes, Optochin (P disk) for
Streptococcus pneumoniae. Identification to genus and species level by BC-GP assay will
divert bacteriologist time from gathering, organizing, and sub-culturing additional media
to setting up a rapid identification assay whose results, available in 2 hours, can be more
clinically relevant than that of a documented tube coagulase result 18 - 24 h after
positivity (Figure 3). The cost of eliminating tube coagulase and disk diffusion test set up
may not be significant enough to offset the overall laboratory cost of implementing a
rapid molecular identification test but when the clinical and economic impact is
analyzed from the perspective of patient care the potential for cost savings can be
significant.
The proposed workflow is not without its challenges. For example, the topic of
continuous workflow, set forth, is not easy to address in large departments with high
specimen volume. To avoid continuous workflow from being met with resistance by
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staff members, the hand-off should be standardized. The main goal of introducing an
end of shift protocol is to set a framework with specific expectations that each shift
must abide to in order for continuous workflow to be effective. Furthermore, in an
effort to standardize the hand-off of pending work, documentation and accountability
of performed tasks are required through the introduction of worksheets presented in
Appendix B,C as well as in pre-integrated LIS scripted workup. Any hand-off isolates
requiring completion of additional tasks by the incoming shift should be clearly
documented both on paper and in LIS. As previously mentioned, the evaluated
reference laboratory gives scheduling priority to the blood culture positive task allowing
for an overlap of bacteriologist between shifts however, scheduling conflicts are
common and can lead to turn-around time delays. A detailed look at the time between
positive flag time and pulled time during shift changes may be necessary to prove the
need for adopting a continuous workflow method. A study performed in an effort to
decrease the time to pathogen identification at a clinical microbiology lab in Houston
Methodist Hospital, found that improving positive blood culture “pull” time can
significantly decrease total processing time (27). Minor changes to the blood culture
work up process at Houston Methodist Hospital lab improved the blood culture “pull”
times from 38 m to 8 m (27). It may be arguable that 30 minutes is not significant
enough to impact patient care but, when mortality rate is increased by turn-around time
delays and time for definitive pathogen identification is prolonged by the unavoidable
pre-analytical aspect of processing a blood culture specimen at a reference laboratory,
the impact can be regarded as more substantial.
Limitations to the BC-GP assay causing discrepancies in reportable results must
be addressed as additional challenges (Table 2). The proposed workflow process has
integrated decision algorithms for both analytical day 1 and analytical day 2 that direct
the bacteriologist to reject or confirm BC-GP assay results respectively depending on
internal control results and phenotypic characteristics (Fig. 5, Fig. 3). LIS reporting
considerations must be taken to acknowledge the risk of false-positive results due to
cross-reactivity between identifiable targets as well as due to its documented poor
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performance in identifying organisms in polymicrobial cultures (17). A report of,
“Presumptive (insert organism and resistance marker if any) identification obtained by
rapid ID method; culture results to follow.”, will be issued on the analytical day 1 of
work up contingent on internal control results. Including “Presumptive” in the initial
preliminary report will allow for confirmation of results on analytical day 2.
Furthermore, as detailed in Figure 5, if controls are “not detected” or a “no call” result is
obtained, repeat testing will not be performed and a result of “Rapid ID unsuccessful;
culture in progress.” will be reported.

Conclusion and outlook
It is impossible to foresee all workflow challenges that may arise when
implementing a new platform thus, the proposed workflow for the integration of the
Verigene BC-GP assay into the established blood-culture work up method at the
evaluated high-volume reference laboratory, is set forth as an initial framework to build
upon. Even if plans to integrate the Verigene assay are not fulfilled, there are a number
of benefits to visually mapping out the current blood culture positive pathway as it has
been done here. Observations to specific potential problem areas were made in this
process analysis and suggestions for improvement presented can be a topic for further
discussion at department meetings.
My recommendation for the high-volume reference laboratory under evaluation
is to try the proposed gram stain suggestions and presented continuous workflow steps
before moving forward with integrating a rapid blood culture identification test. This
may prove beneficial in the long run such that one test of change carried out in small
scale can help anticipate potential problems and will allow staff to more easily adapt to
upcoming changes. A reasonable approach would be to direct one of two scheduled
bacteriologists to adhere to the proposed continuous workflow process while the other
follows established protocol to allow comparisons to be made side by side.
The opportunity to integrate molecular diagnostics into microbiology testing, at
the evaluated high-volume reference laboratory, comes with the need for expansion as
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testing volumes continue to increase. With this opportunity to integrate exciting new
platforms also comes the opportunity to evaluate workflow processes with the end goal
of optimizing a pathway that is known to have a big impact on patient care. Clinical
microbiology laboratories must not forget the role they play in the larger scheme of
patient care and look for ways to evolve with the advancement of molecular technology.
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